News | FFR Technologies | December 16, 2020

Acist Medical Partners With Medis to Distribute Angiography Image Derived FFR Quantification System

The partnership offers alternative QFR to invasive FFR assessment of coronary physiology

The Medis Quantitative Flow Ratio (QFR) is a novel, non-invasive, angiography-based physiologic FFR-like assessment of the presence and extent of coronary artery disease.

The Medis Quantitative Flow Ratio (QFR) is a novel, non-invasive, angiography-based physiologic FFR-like assessment of the presence and extent of coronary artery disease. 

December 16, 2020 – Acist Medical Systems Inc. announced a formal distribution partnership with Medis Medical Imaging to co-market in North America. This partnership is focused on Quantitative Flow Ratio (QFR), a novel, non-invasive, angiography-based physiologic assessment of the presence and extent of coronary artery disease. 

Headquartered in Leiden, Netherlands, Medis has been developing innovative post-processing software for the quantification of cardiovascular images for over 30 years, with QFR as their latest product. The QFR system is am image derived fractional flow reserve (FFR) technology that can measure the amount of blood flow through a coronary lesion or vessel segment to determine if a stent is required or if the patient can be treated medically.

Watch a quick VIDEO example of the QFR technology.

“This strategic collaboration expands our portfolio and enables Acist to better support the evolving needs of our customer. This partnership solidifies Acist’s position as the preferred physiology partner of choice with the ability to offer both invasive and non-invasive approaches to support the clinical utility that physiology provides,” said Brad Fox, president and CEO, Acist Medical Systems Inc.

Medis’ QFR is a proprietary solution delivering image-based functional assessment of coronary obstructions from standard coronary angiograms. The novel QFR approach applies advanced mathematical modeling to accurately and effectively measure the physiologic and anatomical extent of a patient’s coronary artery disease. QFR also improves the patient experience with fast procedure times, no invasive pressure wire, and no required adenosine administration.

According to Morton Kern M.D., chief of cardiology and interventional cardiologist at the VA Long Beach Healthcare System, California, “QFR represents a significant advance for assessment of coronary artery disease in the cath lab. Like other angiographically derived FFR, QFR will let the angiographer see the physiologic impact of the stenoses within a vessel of interest and make an informed decision on whether to stent or not without the need of a pressure wire or adenosine. While still in early clinical use, QFR and other angio-derived FFR systems will become a dominant method in the coming years by improving the patient experience and simplifying PCI decision-making.”

The QFR analysis is performed during the interventional procedure and can streamline workflow in the cath lab while driving economic value. Unlike traditional invasive assessments, including FFR and iFR, the QFR analysis output is co-registered with the angiogram and automatically identifies and prioritizes any functionally significant coronary obstructions. QFR provides the healthcare professional with more extensive and quantitative physiologic imaging results to support the patient’s diagnosis and better inform the patient’s treatment.

“Collaborating with Acist expands our global reach with a proven commercial partner in the USA, helping Medis bring value-based, clinically proven imaging innovation to more clinicians and patients. Introducing QFR in the USA is in line with the aspiration of Medis to establish QFR as the world’s leading technology in angio-based functional assessments,” stated Hans Brons, CEO of Medis.

Watch a quick VIDEO example of the QFR technology.

For more information: medisimaging.comwww.acist.com

 

Related FFR-Angio Content:

Image-based FFR May Replace Pressure Wires and Adenosine

7 Trends in Interventional Lab Angiography Systems

New Technology Directions in Fractional Flow Reserve (FFR)
 

 

Related Content

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021
Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav